Clara Burtenshaw is a Partner and Co-Founder at Neo Kuma Ventures. See contact routes.
Clara Burtenshaw is a Partner and Co-Founder at Neo Kuma Ventures, Europe’s first dedicated psychedelic healthcare venture capital fund based in London, where she leverages a prior career as a corporate lawyer at Slaughter and May and roles as General Counsel for major retail groups to guide early-stage investments. Her investment thesis focuses exclusively on early-stage psychedelic healthcare companies across three categories: compounds, clinics and care delivery, and digital therapeutics, targeting mental health conditions like depression, PTSD, and addiction primarily in Europe with a global outlook. The firm typically invests from pre-seed to Series A with check sizes ranging from £150,000 to £1 million, though specific lead versus follow behavior for Burtenshaw individually is not explicitly detailed in available sources. Notable portfolio companies include Syndi Health, which received a $2.1 million pre-seed grant in February 2023, and Neurocentrx Pharma Ltd, where Burtenshaw serves as Investor Director. Business Insider named Burtenshaw one of the 16 most influential women in psychedelic medicine, reflecting her distinctive point of view on shatt
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in London.
Investors like Clara Burtenshaw · Full investor directory · Investor access · Company funding database